Sign In
Buy SEEL
$0.400
+0 (+0%)
At Close: Feb 14, 2025
Seelos Therapeutics Announces Closing of Public Offering
04:00pm, Friday, 01'st Dec 2023
NEW YORK , Dec. 1, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous syst
Why Are Stocks Up Today?
10:38am, Wednesday, 29'th Nov 2023
Stocks are up today as investors react to the latest comments from members of the Federal Reserve. The most important of these comes from Fed Governor Christopher Waller.
Why Is Seelos Therapeutics (SEEL) Stock Down 42% Today?
08:53am, Wednesday, 29'th Nov 2023
Seelos Therapeutics (NASDAQ: SEEL ) stock is falling on Wednesday after the clinical-stage biopharmaceutical company priced a public offering of its shares. That public offering has Seelos Therapeuti
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
09:26pm, Tuesday, 28'th Nov 2023
NEW YORK , Nov. 28, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous sys
Seelos Therapeutics Announces Proposed Public Offering
04:06pm, Tuesday, 28'th Nov 2023
NEW YORK , Nov. 28, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous sys
- The PTSD-Drug Treatment Program is funded by The U.S. Department of Defense's Defense Health Agency NEW YORK , Nov. 27, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a cl
Seelos Therapeutics Announces 1-for-30 Reverse Stock Split
10:53am, Friday, 24'th Nov 2023
NEW YORK , Nov. 24, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of therapies for ce
Penny Stocks To Buy Under $1? 3 For Your Holiday Watch List
03:14pm, Wednesday, 22'nd Nov 2023
Penny stocks offer investors the chance to get in on the ground floor of small companies with growth potential. They also offer high-volatility trading opportunities daily that can see huge moves of 1
Seelos Therapeutics to Present a Poster on SLS-005 in Alzheimer's Disease at Neuroscience 2023
08:11am, Friday, 27'th Oct 2023
-SLS-005 induces autophagy to reduce mutant protein aggregates, and is currently being studied in Alzheimer's disease, Huntington's disease, Amyotrophic Lateral Sclerosis and Spinocerebellar ataxia NE
Best Penny Stocks This Week? 3 To Watch During Earnings Season
01:48pm, Monday, 23'rd Oct 2023
The process of buying penny stocks is similar to purchasing any other stock shares. The main difference is penny stocks are often not listed on major exchanges like the NYSE and Nasdaq.
Seelos Therapeutics Retains Canaccord Genuity in Connection with Review of Potential Partnerships and Collaborations
08:00am, Tuesday, 17'th Oct 2023
NEW YORK , Oct. 17, 2023 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous sys
Empery Alleges Critical Clinical Trial Misrepresentations by Seelos Therapeutics
10:48am, Tuesday, 10'th Oct 2023
NEW YORK--(BUSINESS WIRE)--Empery Asset Management, LP (“Empery”) wishes to inform shareholders of Seelos Therapeutics, Inc (the “Company” or “Seelos”) that Empery transmitted a letter to
Why Is Seelos Therapeutics (SEEL) Stock Down 25% Today?
09:30am, Thursday, 21'st Sep 2023
Seelos Therapeutics (NASDAQ: SEEL ) stock is falling on Thursday after the company released results from a clinical trial. Seelos Therapeutics first reported results from its Phase 2 trial of SLS-002
Seelos tumbles 66% as depression drug fails after it recruits too few patients
08:33am, Wednesday, 20'th Sep 2023
Seelos Therapeutics (NASDAQ:SEEL) Inc's share price plummeted by 66% pre-market after the company announced that its phase II study for SLS-002, a treatment for adults with major depressive disorder a
Seelos Therapeutics' stock slides 36% after trial of treatment for suicidal ideation has too few patients to meet endpoint
07:46am, Wednesday, 20'th Sep 2023
Seelos Therapeutics Inc.'s stock SEEL tumbled 36% in premarket trade Wednesday, after the company reported promising results from a trial of a treatment for Acute Suicidal Ideation and Behavior (ASIB)
